Prostate-Specific Membrane Antigen (PSMA) Radionuclide Therapy
Reason given: So far, we have not been able to collect meaningful data for these patients which also led to our decision to close this study before attempting write up and publish any results
Key facts
- Where
- Dallas, United StatesSee the site
Where in United States
- Methodist Dallas Medical CenterDallas, United StatesNo longer taking part
Trial details
- Who runs it
- Methodist Health System
- Trial code
- NCT05995236
- Record updated
- 4 August 2026
- Original description
This study is a single-center registry study collecting clinical data regarding the treatment of PSMA-positive metastatic castration-resistant prostate cancer treated with PSMA radionuclide therapy per the treating physician's discretion. Clinical data from candidates for or who undergo the PSMA procedure at Methodist Dallas Medical Center from August 2022 to August 2027 will be collected after discharge and patients will undergo clinical follow-up per the treating physician's discretion.Read full original descriptionShow less
Prostate-Specific Membrane Antigen (PSMA) Radionuclide Therapy for the Treatment of Metastatic Castration-Resistant Prostate Cancer
This study is a single-center registry study collecting clinical data regarding the treatment of PSMA-positive metastatic castration-resistant prostate cancer treated with PSMA radionuclide therapy per the treating physician's discretion. Clinical data from candidates for or who undergo the PSMA procedure at Methodist Dallas Medical Center from August 2022 to August 2027 will be collected after discharge and patients will undergo clinical follow-up per the treating physician's discretion.
Inclusion: 1. >18 years of age; 2. Diagnosed with PSMA-positive metastatic castration-resistant prostate cancer and - has consented to undergo PSMA nuclear therapy per the treating physician. Specifically:; Metastatic or Locally Advanced AND Inoperable; Clear disease progression on PSMA-PET/CT; PSMA-PET/CT scan positive disease within 6 weeks; Labs:; Hemoglobin: >8 g/dL; White blood cell count: >2K cells/µL; Platelet (Thrombocyte) count: >75 x 109/L; No prior therapy with Radium-223 Dichloride.
Exclusion: Patients who do not meet the Inclusion Criteria laid out in section 4.2 will be excluded from the study.